Remibrutinib, a Novel Highly Selective and Potent BTKi in Development for MS: Analysis of Safety Data from the Completed Phase 2 Studies in Other Inflammatory Immune-Mediated Diseases
MULTIPLE SCLEROSIS JOURNAL（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined